Press Releases


All Releases | Reset Search
Acquisitions | Business/Product | Corporate | Financial

2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009
09/03/15Pfizer Conclut L'Acquisition De HospiraPrinter Friendly Version
09/03/15Pfizer Completes Acquisition of Hospira Printer Friendly Version
08/27/15Hospira Announces First Installation of Plum 360™ Infusion System With Hospira MedNet™Printer Friendly Version
08/25/15Hospira and Cerner Expand Agreement to Advance Integration of I.V.-EMR TechnologyPrinter Friendly Version
08/21/15Expert committee BACKS Hospira’s InflectraTMPrinter Friendly Version
08/20/15Charleston Area Medical Center Integrates Smart Pump Technology To Advance Patient SafetyPrinter Friendly Version
08/19/15TGA Approves First Mab BiosimilarPrinter Friendly Version
08/13/15Hospira Applauds UK's NICE for Issuing Adoption Resource to Help Drive the Introduction of Biosimilars Printer Friendly Version
07/29/15Hospira Reports Second-Quarter 2015 ResultsPrinter Friendly Version
07/16/15Hospira Announces U.S. Launch of Generic Bivalirudin for InjectionPrinter Friendly Version
07/15/15Hospira to Announce Second-Quarter 2015 Results on July 29, 2015Printer Friendly Version
06/10/15New results from first real-world study show comparable effectiveness and safety of Hospira's Inflectra™ (infliximab) in patients with rheumatic diseases switched from reference infliximab, Remicade™Printer Friendly Version
06/02/15ANVISA Approves First Infliximab Biosimilar in BrazilPrinter Friendly Version
05/20/15Hospira, Alliance for Health Reform Bring Food and Drug Administration, Industry Experts Together to Discuss the Future of Biosimilars in the United StatesPrinter Friendly Version
05/13/15Hospira Shareholders Approve Merger of Hospira and Pfizer at Special MeetingPrinter Friendly Version
05/01/15 Hospira Statement On FDA's Final Biosimilar Guidance DocumentsPrinter Friendly Version
04/28/15Hospira Reports First-Quarter 2015 ResultsPrinter Friendly Version
04/24/15Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on ExtrapolationPrinter Friendly Version
04/13/15Hope for Greater Access for Patients to Biosimilar MedicinesPrinter Friendly Version
04/07/15Hospira to Announce First-Quarter 2015 Results on April 28, 2015Printer Friendly Version
03/30/15Hospira's INFLECTRA™ (Infliximab) Now Available in CanadaPrinter Friendly Version
03/30/15Inflectra™ (Infliximab) De Hospira Est Désormais Printer Friendly Version
03/27/15Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's EpogenPrinter Friendly Version
03/06/15Hospira Statement on FDA Approval of the First Biosimilar in the United StatesPrinter Friendly Version
02/19/15Inflectra™ (infliximab) patient registry reports interim results in the treatment of inflammatory bowel diseasePrinter Friendly Version
02/16/15Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European marketsPrinter Friendly Version
02/12/15Hospira Reports Fourth-Quarter and Full-Year 2014 ResultsPrinter Friendly Version
02/10/15Pfenex And Hospira Announce Collaboration To Develop And Commercialize Proposed LUCENTIS® BiosimilarPrinter Friendly Version
02/09/15Hospira Cancels Previously Scheduled Conference Call to Discuss Fourth-Quarter and Full-Year 2014 ResultsPrinter Friendly Version
02/05/15Pfizer To Acquire Hospira Printer Friendly Version
01/29/15Hospira to Host Conference Call for Fourth-Quarter 2014 Results and 2015 ProjectionsPrinter Friendly Version
01/20/15Hospira Receives FDA Clearance for Plum 360™ Infusion SystemPrinter Friendly Version
01/12/15Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa BiosimilarPrinter Friendly Version
01/11/15Hospira Statement On FDA Advisory Committee's Recommendation To Approve The First U.S. BiosimilarPrinter Friendly Version
01/08/15Hospira Announces Significant Progess On Global Device StrategyPrinter Friendly Version